glp-1 shortage fda As Drug Ends, Why Will Patients Pay More? What Patients Need to Know

NADPH oxidase 3 (NOX3) and superoxide dismutase 2 (SOD2) levels were decreased by GLP-1 therapy

Thus, the technical advances in understanding the distribution and functional roles of GLP-1R across peripheral and central systems continue to inform the development of more effective therapies targeting both metabolic and behavioral domains

Cyber Resilience Our Cyber Resilience collection gives you access to Aons latest insights on the evolving landscape of cyber threats and risk mitigation measures

doi: 10.1016/S0021-9258(18)67561-1 45 HeinrichGGrosPHabenerJF

PuhlHL IIIWonYJLuVBIkedaSR

Why Brand-Name Cant Match Price Structural Barriers: Public Company Obligations: Must maximize shareholder return Quarterly earnings pressure Executive compensation tied to profits Cant dramatically reduce price without stock impact Sunk Costs: Billions invested in development Need to recoup investment Justify to shareholders and board Complex Distribution System: PBMs demand rebates Wholesalers take cut Pharmacy margins Cant easily change system Market Dynamics: Limited competition (patent protection) Can charge premium prices Demand exceeds supply No pressure to reduce Eli Lilly unlikely to reduce tirzepatide prices significantly while patents protected